Psychedelic drugs for psychiatric disorders.

da Costa, Sabrina Correa; Oesterle, Tyler; Rummans, Teresa A; Richelson, Elliot; Gold, Mark

da Costa, Sabrina Correa; Oesterle, Tyler; Rummans, Teresa A; Richelson, Elliot; Gold, Mark.

Afiliación

da Costa SC; Department of Psychiatry and Psychology, Mayo Clinic Health System, La Crosse, WI, United States of America. Electronic address: Correadacosta.sabrina@mayo.edu.
Oesterle T; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
Rummans TA; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
Richelson E; Department of Psychiatry and Psychology, Mayo Clinic Florida, Jacksonville, FL, United States of America.
Gold M; University of Florida & McKnight Brain Institute, Department of Psychiatry and National Council, Institute for Public Health, Washington University in St Louis School of Medicine, United States of America.

J Neurol Sci ; 440: 120332, 2022 09 15.

Article en En | MEDLINE | ID: mdl-35841696

Asunto(s)

Alcoholismo; Alucinógenos; Trastornos Mentales; Alucinógenos/farmacología; Alucinógenos/uso terapéutico; Humanos; Dietilamida del Ácido Lisérgico/farmacología; Dietilamida del Ácido Lisérgico/uso terapéutico; Trastornos Mentales/tratamiento farmacológico; Psilocibina/farmacología; Psilocibina/uso terapéutico

Palabras clave

Hallucinogens; LSD; MDMA (ecstasy); Psilocybin; Psychedelic-assisted psychotherapy; Psychedelics; Psychiatric disorders

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Alcoholismo / Alucinógenos / Trastornos Mentales Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Neurol Sci Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google